Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside

被引：38
|
作者：
Furukawa, Toru [1 ]
机构：
[1] Tokyo Womens Med Univ, Int Res & Educ Inst Integrated Med Sci, Shinjuku Ku, Tokyo 1628666, Japan
来源：
JOURNAL OF GASTROENTEROLOGY | 2008年 / 43卷 / 12期
关键词：
pancreatic cancer; molecular targeting; RAS-MAPK; PI3K-AKT; hedgehog;
D O I：
10.1007/s00535-008-2226-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Current medical interventions for pancreatic cancer are insufficient. Recent molecular investigations have elucidated complex genetic mechanisms of cancer that especially involve multiple signal transduction pathways; this enables us to develop molecular medicines targeting specific genetic molecules in the pathways. These molecular medicines seem to promise clues for curing cancers, including pancreatic cancer. This review describes current knowledge and perspectives regarding the development of molecular medicines for pancreatic cancer by focusing on growth factor receptor systems and three major signal transduction pathways: the RAS-MAPK, PI3K-AKT-mTOR, and hedgehog pathways.
引用
收藏
页码：905 / 911
页数：7
相关论文
共 50 条
  • [31] Natalizumab: Perspectives from the Bench to Bedside
    Shirani, Afsaneh
    Stuve, Olaf
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2018, 8 (12):
  • [32] Molecular targeting therapy for pancreatic cancer
    Xiong, HQ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (Suppl 1) : S69 - S77
  • [33] Gene therapy targeting hematopoietic stem cells: From the bench to the bedside
    Cavazzana-Calvo, M.
    Hacein-Bey-Abina, S.
    Garrigue, A.
    Wang, G.
    Bushman, F.
    Fischer, A.
    BLOOD CELLS MOLECULES AND DISEASES, 2008, 40 (02) : 259 - 259
  • [34] Molecular targeting therapy for pancreatic cancer
    Henry Q. Xiong
    Cancer Chemotherapy and Pharmacology, 2004, 54 : S69 - S77
  • [35] Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside
    Xu, Yan
    CANCERS, 2019, 11 (10)
  • [36] Targeting the IDO1 pathway in cancer: from bench to bedside
    Ming Liu
    Xu Wang
    Lei Wang
    Xiaodong Ma
    Zhaojian Gong
    Shanshan Zhang
    Yong Li
    Journal of Hematology & Oncology, 11
  • [37] Targeting the IDO1 pathway in cancer: from bench to bedside
    Liu, Ming
    Wang, Xu
    Wang, Lei
    Ma, Xiaodong
    Gong, Zhaojian
    Zhang, Shanshan
    Li, Yong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [38] MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside
    Kenneth KW To
    Christy WS Tong
    Mingxia Wu
    William CS Cho
    World Journal of Gastroenterology, 2018, 24 (27) : 2949 - 2973
  • [39] MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside
    To, Kenneth K. W.
    Tong, Christy W. S.
    Wu, Mingxia
    Cho, William C. S.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (27) : 2949 - 2973
  • [40] Natural isoflavonoids in invasive cancer therapy: From bench to bedside
    Cayetano-Salazar, Lorena
    Olea-Flores, Monserrat
    Zuniga-Eulogio, Miriam D.
    Weinstein-Oppenheimer, Caroline
    Fernandez-Tilapa, Gloria
    Mendoza-Catalan, Miguel A.
    Zacapala-Gomez, Ana E.
    Ortiz-Ortiz, Julio
    Ortuno-Pineda, Carlos
    Navarro-Tito, Napoleon
    PHYTOTHERAPY RESEARCH, 2021, 35 (08) : 4092 - 4110
12345